|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
For this reason, it was suggested that immunohistochemistry against IDH1 R132H is sufficient to classify GBM as IDH wild-type in this age group.
|
31758617 |
2020 |
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
|
30760578 |
2019 |
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Mutations in the isocitrate dehydrogenase (IDH) 1 gene are commonly found in human glioma, with the majority of low-grade gliomas harboring a recurrent point mutation (IDH1 R132H).
|
31768950 |
2019 |
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Isocitrate dehydrogenase (IDH) is mutated in >80% of lower-grade infiltrating gliomas in adults and in ~10% of glioblastomas, with IDH1 (R132H) being the most common mutation.
|
30221786 |
2019 |
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We analyzed patients with newly diagnosed GBM and excluded patients who presented with IDH1 R132H mutations.
|
29617848 |
2019 |
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Additionally, 5-aza enhances the therapeutic effect of the DNA damaging agent TMZ in both subcutaneous and orthotopic PDX models of IDH1 R132H mutant glioma.
|
30184215 |
2019 |
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.
|
31292202 |
2019 |
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Tumor-to-muscle ratios were also significantly higher in U251/IDH1 R132H tumo</span>rs (3.36 ± </span>0.41 vs. 1.88 ± 0.59, p = 0.0030).
|
31667733 |
2019 |
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In 1 case, an IDH1 R132H-mutant glioma was misdiagnosed as a demyelinating condition by frozen section histology during the intraoperative consultation, and no resection was performed pending the final pathology report.
|
30611146 |
2019 |
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
R132H mutation of isocitrate dehydrogenase 1 (IDH1) is found in ~75% of low-grade gliomas and secondary glioblastomas as well as in several other types of cancer.
|
29792149 |
2018 |
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
<i>IDH1</i> mutations only affected brainstem gliomas (6/24 vs 0/78; <i>p</i> = 7.5 × 10<sup>-5</sup>), were mostly non-R132H (contrasting with hemispheric gliomas, <i>p</i> = 0.0001), and were associated with longer survival (54 vs 12 months).
|
29728520 |
2018 |
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We found that both low-grade and high-grade (i.e., GBM) IDH1 R132H gliomas exhibit low Fn14 mRNA and protein levels compared to IDH1 WT gliomas.
|
29453678 |
2018 |
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
These results support a role for Fn14 in the more aggressive and invasive phenotype associated with IDH1 WT tumors and indicate that the low levels of Fn14 gene expression noted in IDH1 R132H mutant gliomas may be due to epigenetic regulation via changes in DNA methylation.
|
29453678 |
2018 |
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In the subgroup of 142 glioma patients characterized by IDH1-R132H status, METT/N ratio demonstrated a significant prognostic impact in IDH1-R132H wildtype astrocytomas and glioblastoma (P = 0.001).
|
29016947 |
2018 |
|
Astrocytoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Of these, we recommend, OA,NOS and IDH1(R132H)-non-mt ODG,NOS to be our priority for performing 1p/19q co-deletion studies in comparison to IDH-mt ODG,NOS, and it would not be mandatory for astrocytoma.
|
28801347 |
2018 |
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
This novel series of IDH1(R132H) inhibitors have potential to be further developed for the treatment of glioma with IDH1 mutation.
|
29792149 |
2018 |
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Low-grade gliomas (WHO II/III) had lower xCT expression than glioblastoma (p = 0.001), and tumors without IDH1 R132H mutation tended to have higher xCT levels (p = 0.07).
|
29404978 |
2018 |
|
Astrocytoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In the subgroup of 142 glioma patients characterized by IDH1-R132H status, METT/N ratio demonstrated a significant prognostic impact in IDH1-R132H wildtype astrocytomas and glioblastoma (P = 0.001).
|
29016947 |
2018 |
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Mutation of the isocitrate dehydrogenase 1 (IDH1) gene at codon 132 has been identified in approximately 70% of low-grade (II and III) human gliomas and secondary glioblastomas, with the IDH1 R132H point mutation representing 92.7% of these mutations.
|
30502793 |
2018 |
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Patients/Methods In a prospective cohort study, intratumoral IDH1 R132H mutation and podoplanin were determined in brain tumor specimens (mainly glioma) by immunohistochemistry.
|
29676036 |
2018 |
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The findings of the current study demonstrate presence of the IDH1 R132H mutation in primary human glioblastoma cell lines with upregulated HIF-1α expression, downregulating c-MYC activity and resulting in a consequential decrease in miR-20a, which is responsible for cell proliferation and resistance to standard temozolomide treatment.
|
29625108 |
2018 |
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Sequencing for rare IDH mutations is advised for A,NOS and OA,NOS groups, but not for the IDH1(R132H)-non-mutant diffuse gliomas with 1p/19q co-deletion.
|
28801347 |
2018 |
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Mutated IDH1 R132H protein and H3F3A K27M mutations indicate that a substantial number of GBMc are "metastatic" or "diaschismatic" lesions.
|
30203362 |
2018 |
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Recurrent heterozygous mutation of isocitrate dehydrogenase 1 gene (<i>IDH1</i>), predominantly resulting in histidine substitution at arginine 132, was first identified in glioma.
|
30416682 |
2018 |
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The R132H mutation in isocitrate dehydrogenase 1 (IDH1-R132H) is associated with better prognosis in glioma patients.
|
29115585 |
2018 |